Edgewise investors back board, auditor and pay

Edgewise Therapeutics, Inc. reported results of its Annual Meeting of stockholders held on June 4, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. reported results of its Annual Meeting of stockholders held on June 4, 2026. Stockholders elected three Class II directors — Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D. — to serve until the 2029 annual meeting, with each to continue until a successor is elected and qualified.

Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 99,637,228 votes for, 1,123 against, and 578,031 abstaining. In addition, stockholders approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, with 87,055,111 votes for, 3,491,326 against, and 577,257 abstaining.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for KPMG LLP: 99,637,228 votes Votes for executive compensation: 87,055,111 votes Votes for Laura Brege: 87,300,827 votes +2 more

5 metrics

Votes for KPMG LLP 99,637,228 votes Ratification of auditor for fiscal year ending December 31, 2026

Votes for executive compensation 87,055,111 votes Advisory vote on named executive officers’ compensation

Votes for Laura Brege 87,300,827 votes Election as Class II director until 2029 annual meeting

Votes for Badreddin Edris, Ph.D. 64,082,681 votes Election as Class II director until 2029 annual meeting

Votes for Jonathan Root, M.D. 59,213,781 votes Election as Class II director until 2029 annual meeting

Key Terms

Annual Meeting of stockholders, independent registered public accounting firm, advisory and non-binding basis, named executive officers, +1 more

5 terms

Annual Meeting of stockholders financial

"Edgewise Therapeutics, Inc. (the “Company”) held its Annual Meeting of stockholders"

independent registered public accounting firm financial

"the appointment of KPMG LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

advisory and non-binding basis financial

"The stockholders approved, on an advisory and non-binding basis, the compensation"

named executive officers financial

"the compensation of the Company’s named executive officers"

Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.

Class II Directors financial

"Proposal 1: Election of three Class II Directors"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Edgewise Therapeutics (EWTX) stockholders approve at the 2026 Annual Meeting?

Edgewise Therapeutics stockholders elected three Class II directors, ratified KPMG LLP as auditor for 2026, and approved, on an advisory and non-binding basis, the compensation of named executive officers. These actions confirm the company’s proposed board, auditor, and executive pay program.

Who was elected to the Edgewise Therapeutics (EWTX) board in 2026?

Stockholders elected Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D., as Class II directors to serve until the 2029 annual meeting. Each director will continue in office until a successor is duly elected and qualified, subject to earlier resignation or removal under company governance.

Which auditor did Edgewise Therapeutics (EWTX) stockholders ratify for 2026?

Stockholders ratified KPMG LLP as Edgewise Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote totaled 99,637,228 shares for, 1,123 against, and 578,031 abstaining, indicating strong stockholder support for continuing with the same audit firm.

How did Edgewise Therapeutics (EWTX) stockholders vote on executive compensation in 2026?

Stockholders approved, on an advisory and non-binding basis, the compensation of Edgewise Therapeutics’ named executive officers. The vote was 87,055,111 shares for, 3,491,326 against, and 577,257 abstaining, showing broad but not unanimous support for the company’s executive pay practices at this meeting.

When will the newly elected Edgewise Therapeutics (EWTX) directors’ terms expire?

The three elected Class II directors will serve until the 2029 annual meeting of stockholders. Their service continues until their successors are duly elected and qualified, or until earlier resignation or removal, following the company’s standard board term and transition framework.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/05/2026 - 04:33 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 4, 2026

Edgewise Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40236

82-1725586

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer
Identification No.)

1715 38th St.

Boulder, CO 80301

(Address of principal executive offices) (Zip Code)

(720) 262-7002

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		EWTX		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07.

SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

Edgewise Therapeutics, Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 4, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.

Proposal 1: Election of three Class II Directors

Name of Director	For		Withheld
Laura Brege		87,300,827	3,822,867
Badreddin Edris, Ph.D.		64,082,681	27,041,013
Jonathan Root, M.D.		59,213,781	31,909,913

Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.

Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm

For			Against			Abstain
99,637,228			1,123			578,031

The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Proposal 3: Advisory Vote on the Compensation of the Company’s Named Executive Officers

For			Against			Abstain
87,055,111			3,491,326			577,257

The stockholders approved, on an advisory and non-binding basis, the compensation of the Company’s named executive officers.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EDGEWISE THERAPEUTICS, INC.

	By:	/s/ Kevin Koch
		Kevin Koch, Ph.D.
		President and Chief Executive Officer

Date: June 5, 2026

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents